[go: up one dir, main page]

WO2025166015A3 - Bifunctional abl1-binding compounds and uses thereof - Google Patents

Bifunctional abl1-binding compounds and uses thereof

Info

Publication number
WO2025166015A3
WO2025166015A3 PCT/US2025/013801 US2025013801W WO2025166015A3 WO 2025166015 A3 WO2025166015 A3 WO 2025166015A3 US 2025013801 W US2025013801 W US 2025013801W WO 2025166015 A3 WO2025166015 A3 WO 2025166015A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphorylation
compounds
abl1
substrate
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/013801
Other languages
French (fr)
Other versions
WO2025166015A2 (en
Inventor
Florence Fevrier WAGNER
Dominique Potin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photys Therapeutics Inc
Original Assignee
Photys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photys Therapeutics Inc filed Critical Photys Therapeutics Inc
Publication of WO2025166015A2 publication Critical patent/WO2025166015A2/en
Publication of WO2025166015A3 publication Critical patent/WO2025166015A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are compounds that bind 3-phosphoinositide- dependent protein kinase-1 (ABL1) and/or promote targeted phosphorylation of a substrate. The induced phosphorylation of the target substrate can alter the substrate's structure and function, thus providing compounds which enable phosphorylation of target substrates, including those that may not otherwise be substrates for ABL1, and providing new modes for inducing strategic phosphorylation. Also provided are compounds that are intermediates of the bifunctional compounds. Also provided are compounds that bind an allosteric site of ABL1 and inhibit the phosphorylation of a target substrate. Also provided are pharmaceutical compositions comprising the disclosed compounds and methods of promoting the phosphorylation of target substrates in a biological sample by administering a compound or composition described herein.
PCT/US2025/013801 2024-02-02 2025-01-30 Bifunctional abl1-binding compounds and uses thereof Pending WO2025166015A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463549396P 2024-02-02 2024-02-02
US63/549,396 2024-02-02

Publications (2)

Publication Number Publication Date
WO2025166015A2 WO2025166015A2 (en) 2025-08-07
WO2025166015A3 true WO2025166015A3 (en) 2025-09-12

Family

ID=94871415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/013801 Pending WO2025166015A2 (en) 2024-02-02 2025-01-30 Bifunctional abl1-binding compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2025166015A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496100A1 (en) * 1980-12-16 1982-06-18 Wellcome Found PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE SUBSTANCES
EP0127371A2 (en) * 1983-05-21 1984-12-05 FISONS plc 1,N-diaryl-4,5-dihydro-1H-pyrazol-3-amines, compositions containing them and methods for their preparation
EP0178035A1 (en) * 1984-05-12 1986-04-16 FISONS plc Anti-inflammatory 1,N-diarylpyrazol-3-amines, compositions containing them and processes for their preparation
WO1990014338A1 (en) * 1989-05-20 1990-11-29 Fisons Plc Anti-inflammatory 4-aminophenol derivatives
WO2006122011A2 (en) * 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
US20240024490A1 (en) * 2021-04-09 2024-01-25 The Broad Institute, Inc. Bifunctional molecules for selective modification of target substrates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496100A1 (en) * 1980-12-16 1982-06-18 Wellcome Found PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE SUBSTANCES
EP0127371A2 (en) * 1983-05-21 1984-12-05 FISONS plc 1,N-diaryl-4,5-dihydro-1H-pyrazol-3-amines, compositions containing them and methods for their preparation
EP0178035A1 (en) * 1984-05-12 1986-04-16 FISONS plc Anti-inflammatory 1,N-diarylpyrazol-3-amines, compositions containing them and processes for their preparation
WO1990014338A1 (en) * 1989-05-20 1990-11-29 Fisons Plc Anti-inflammatory 4-aminophenol derivatives
WO2006122011A2 (en) * 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
US20240024490A1 (en) * 2021-04-09 2024-01-25 The Broad Institute, Inc. Bifunctional molecules for selective modification of target substrates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRIGOLAR ET AL: "Synthesis, structure and inhibitory effects on cyclooxygenase, lipoxygenase, thromboxane synthetase and platelet aggregation of 3-amino-4,5-dihydro-1H-pyrazole derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 24, 1 January 1989 (1989-01-01), pages 435 - 445, XP093278752 *

Also Published As

Publication number Publication date
WO2025166015A2 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
TWI663975B (en) Methods of treating liver disease
US9289415B2 (en) Treatment of cancer
ATE322264T1 (en) MEDICAL COMPOSITIONS AS COMPANIONARY THERAPY AGAINST CANCER
US10905665B2 (en) Chemical modulators of signaling pathways and therapeutic use
Nguyen Targeting RSK: an overview of small molecule inhibitors
EA200400953A1 (en) SUBSTITUTED PYRIDINOES AS MAP-KINASE P38 MODULATORS
WO2002100845A8 (en) Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
A. Kulchitsky et al. Cytotoxic effects of chemotherapeutic drugs and heterocyclic compounds at application on the cells of primary culture of neuroepithelium tumors
Cunningham et al. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors
AU784426C (en) Tissue factor antagonists and methods of use thereof
Huitema et al. The clinical pharmacology of alkylating agents in high-dose chemotherapy
Hernández-Reséndiz et al. Reduction of no-reflow and reperfusion injury with the synthetic 17β-aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade
WO2020170202A1 (en) Kinase inhibitors
EP1732569B1 (en) Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
EA200500095A1 (en) DERIVATIVES 4- (7-GALO-2-HINO (KSA-) LINOILOXY) PHENOXYPROPIONIC ACID AS ANTI-TUMOR MEDIA
EP2210643A3 (en) Combinations comprising epothilones and pharmaceutical uses thereof
WO2025166015A3 (en) Bifunctional abl1-binding compounds and uses thereof
Kostapanos et al. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress
EA200601687A1 (en) Tetrahydroisoquinoline TETRAGIDROBENZAZEPINOVYE AND DERIVATIVES (OPTIONS), pharmaceutical compositions and pharmaceutical kits, medicinal and reference instruments for the test-systems based on them, methods of treatment and prevention of diseases in which the down-regulation of a favorable or inhibiting the expression or function of IGF-1 Receptor
JP2008523138A (en) Method of activating bone formation pathway by BMP by acetylating Runx2 to increase Runx2 activity
TW200306853A (en) Therapeutic agent for glomerular disease
MEP0408A (en) Spirocyclic quinazoline derivatives as pde7 inhibitors
KR20160083806A (en) Composition for treating and preventing of cholesterol related to disease
WO2025019599A3 (en) Bifunctional kinase binding compounds and uses thereof
UA84020C2 (en) Entry inhibitors of the hiv virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25710163

Country of ref document: EP

Kind code of ref document: A2